Johnson Matthey has announced the appointment of Nicholas Shackley to the role of Global Vice President Innovator Products and Solutions.
In this role Nicholas will lead Johnson Matthey’s (JM) custom development and manufacturing offering to pharmaceutical and biotechnology customers who are developing novel therapies and innovative medication.
This offering includes a broad range of enabling technologies and extensive global facilities including R&D centres located in Devens, Massachusetts and Cambridge, UK as well as manufacturing sites in West Deptford, New Jersey; Conshohocken, Philadelphia; North Andover, Massachusetts; and Annan, Scotland. In addition to the existing offer, Nicholas will be responsible for growing the capabilities through addition of new technologies and assets to service the expanding market for technology-enabled custom development and manufacturing solutions.
Nicholas brings a wealth of experience to JM, having most recently held the positon of Senior Vice President at Aceto Corporation where he was responsible for the pharmaceutical ingredients businesses. Prior to this he has had senior positions at BASF, Cambrex and Avecia and holds a BEng from Imperial College, London.
“We are excited to have Nicholas join our Health sector in this critical position,” commented Robert MacLeod, Chief Executive of JM. “His extensive knowledge of the pharmaceutical innovator market coupled with his senior leadership skills will be invaluable in driving our strategic growth-providing solutions to the clinical development and commercial manufacturing needs of the pharma and biotech industries.”
Source: Johnson Matthey
Corteva (Indianapolis, Indiana) says it has signed a definitive agreement to acquire Stoller Group (Houston, Texas), a producer of biostimulants and plant nutrition products, for $1.2 billion. Stoller is one of the largest independent biologicals companies globally, with operations in more than 60 countries and more than $400 million in annual sales.
OMV has announced its new corporate structure today, designed to fully enable the delivery of Strategy 2030. The new organization will be built on five distinct areas. In addition to the CEO and CFO areas, three business segments will be established: Chemicals & Materials, Fuels & Feedstock, and Energy.
The European petchem sector is readying for some tough quarters. It’s a different picture in the US. So is this the best time ever to find a new role in the chemical industry? If you are in Europe, you would expect me to say probably not. But actually, it depends. So let me give you four answers to this question.